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A B S T R A C T   
MYBPC3 is the most frequently affected gene in hypertrophic cardiomyopathy (HCM), which is an autosomal-dominant cardiac disease caused by mutations in 
sarcomeric proteins. Bi-allelic truncating MYBPC3 mutations are associated with severe forms of neonatal cardiomyopathy. We reprogrammed skin fibroblasts from a 
HCM patient carrying a heterozygous MYBPC3 truncating mutation into human induced pluripotent stem cells (iPSC) and used CRISPR/Cas9 to generate bi-allelic 
MYBPC3 truncating mutation and isogenic control hiPSC lines. All lines expressed pluripotency markers, had normal karyotype and differentiated into endoderm, 
ectoderm and cardiomyocytes in vitro. This set of three lines provides a useful tool to study HCM pathomechanisms.   
Resource Table  
Unique stem cell lines identifier  1. UKEi070-A  
2. UKEi070-A1  
3. UKEi070-A2 
Alternative name(s) of stem cell lines 1. Het 2. Iso Co 3. cpHet 
Institution Institute of Experimental Pharmacology 
and Toxicology, University Medical 
Center Hamburg-Eppendorf, Hamburg, 
Germany 
Contact information of the reported cell 
line distributor 
Prof. Dr. Lucie Carrier; l.carrier@uke.de 
Type of cell lines iPSC 
Origin Human 
Additional origin info Age: 53 
Female 
Central America 
Cell Source Dermal fibroblasts 
Method of reprogramming 
(continued on next column) 
Resource Table (continued ) 
Non-integrating Sendai virus vectors 
(CytoTune TM, expression of OCT-4, 
SOX2, c-MYC, KLF4) 
Clonality Clonal 
Evidence of the reprogramming 
transgene loss (including genomic 
copy if applicable) 
RT-qPCR Sendai virus – negative at 
Master Cell Bank stage 
Cell culture system used Conditioned medium (young clones), 
maintenance in FTDA culture medium 
Type of Genetic Modification Induced homozygous mutation (bi-allelic 
mutant hiPSC line) and gene correction 
(isogenic control) 
Associated disease Hypertrophic cardiomyopathy (CMH4; 
115197) 
Gene/locus MYBPC3/chr11 (p11.2):   
- Heterozygous c.2308G>A, p. 
Asp770Serfs98X (patient) 
(continued on next page) 
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Resource Table (continued )  
- Isogenic control for c.2308G+6 G>T 
(wild-type plus silent mutation)  
- Compound heterozygous: c.2308G>A, 
p.Asp770Serfs98X (heterozygous) and 
c.2827C>T, p.Arg943Ter 
(homozygous) 
Method of modification/site-specific 
nuclease used 
CRISPR/Cas9 
Site-specific nuclease (SSN) delivery 
method 
Nucleofection of RNP 
All genetic material introduced into the 
cells 
RNP complex (crRNA, tracrRNA and Cas9 
nuclease) and 120-mer ssODNs for HDR 
Analysis of the nuclease-targeted allele 
status 
Sanger sequencing of the targeted locus 
and bacterial subcloning 
Method of the off-target nuclease 
activity surveillance 
Targeted PCR and Sanger sequencing of 
the Top10 off-target loci 
Name of transgene N/A 
Eukaryotic selective agent resistance 
(including inducible/gene expressing 
cell-specific) 
N/A 
Inducible/constitutive system details N/A 
Date archived/stock date UKEi070-A (Het): 11/04/2018 UKEi070- 
A-1 (Iso Co): 19/07/2018 UKEi070-A-2 
(cpHet): 14/09/2018 
Cell line repository/bank No repository/bank 
Ethical/GMO work approvals The patient gave her written informed 
consent for research purposes and the 
study was approved by the ethical 
committee of the UKE, Hamburg 
(PV3501). 
Addgene/public access repository 
recombinant DNA sources’ 
disclaimers (if applicable) 
N/A   
1. Resource utility 
The three hiPSC lines provide an everlasting source for differentia-
tion into cardiomyocytes for HCM disease modelling. The combination 
of heterozygous and compound heterozygous MYBPC3 truncating mu-
tations with their isogenic control allows to study the effect of MYBPC3 
gene dosage on HCM pathomechanisms and to test new therapeutic 
options. 
2. Resource details 
HCM is widely heterogenous in its clinical manifestations, ranging 
from no symptoms to sudden death. Most patients carry heterozygous 
mutations and have a late onset of the disease. In contrast, a minority of 
patients carrying compound heterozygous or homozygous truncating 
MYBPC3 mutations leading to the complete absence of protein presents 
with a severe cardiomyopathy already at birth, which rapidly develops 
into heart failure and death within the first year of life (reviewed in 
Carrier, 2021). Heart transplantation remains the only curative treat-
ment for these infants. The pathogenic heterozygous MYBPC3 mutation 
(c.2308G>A; p.Asp770Serfs98X) was identified in a HCM patient 
recruited in the outpatient clinic at the University Heart Center 
Hamburg (Table 1). This mutation is located on the last nucleotide of 
exon 23 and is considered truncating (Helms et al., 2014). Patient- 
derived fibroblasts were reprogrammed into hiPSC with Sendai Virus 
and used as parental line (Het) to generate MYBPC3-corrected iPSC line 
(isogenic control, Iso Co) via CRISPR/Cas9 genome editing. In addition, 
the Dutch founder nonsense mutation c.2827C>T, p.Arg943Ter 
(Christiaans et al., 2010) was introduced at the homozygous state in Het 
hiPSC to generate a bi-allelic mutant (cpHet) hiPSC line, to recapitulate 
the genetic situation of infants with severe forms of cardiomyopathy 
(Fig. 1A). 
The three hiPSC lines were validated for essential features (Table 2). 
They showed a typical stem cell morphology and normal karyotypes 
(Fig. 1B, C). Sanger sequencing confirmed the heterozygous mutation in 
Het, and the expected CRISPR/Cas9 genetic modifications of the Iso Co 
and cpHet hiPSC lines (Fig. 1D). FACS analysis revealed a high per-
centage of positive cells for the pluripotency marker SSEA3 in all lines 
(>80%; Fig. 1E), and RT-PCR analysis showed the expression of other 
pluripotency markers, NANOG and SOX2 (Fig. 1F). Extensive evaluation 
of differentiation potential has been performed for the parental Het line 
comparing by RT-qPCR gene expression of specific markers before and 
after differentiation (Fig. 1F). In addition specific expression in the 
relative lineages has been verified by RT-PCR in Het and in the two 
subclones Iso Co and cpHet (Fig. 1G). Furthermore the hiPSC lines were 
capable of differentiating into cardiomyocytes as shown by the high 
percentage of cardiac troponin T (cTnT)-positive cells (Fig. 1H). Off- 
target analysis showed no effects in the Top10 analysed loci, suggest-
ing high fidelity of the RNP-based CRISPR approach (Suppl. Fig. 1). STR 
analysis proved that the genetically modified hiPSC lines originate from 
the Het (data provided to hiPSCreg). Protein lysate of hiPSC-derived 
cardiomyocytes (hiPSC-CMs) showed complete absence of MYBPC3 
protein in cpHet (Fig. 1I). 
3. Materials and methods 
3.1. Reprogramming and culture 
Dermal fibroblasts were obtained from a skin biopsy taken from the 
HCM patient and were used for reprogramming with the CytoTune-iPS 
Sendai Reprogramming Kit (#A1377801, Life Technologies) according 
to the manufacturer’s instructions. The hiPSCs were cultured on 
Matrigel-coated plates containing conditioned medium. Passaging was 
performed twice a week with Accutase™ supplemented with Rock in-
hibitor (10 µM Y-27632). The medium was replaced daily and hiPSC 
were cultured under hypoxic conditions (37 ◦C, 5% CO2 and 5% O2). 
From passage 19 onwards, hiPSC were adapted to FTDA culture medium 
and cultured on Geltrex-coated culture plates. Master cell banks were 
created as previously described (Shibamiya et al. 2020). 
3.2. Genetic modification using CRISPR/Cas9 
For genetic modification two gRNAs were designed with the CRISPR 
design tool http://crispr.mit.edu/ (Table 3). Electroporation was per-
formed in hiPSC Het (passage 19) using the 4D-NucleofectorTM System 
(Lonza). Nucleofected cells were plated on Matrigel-precoated 12-well 
plates and after 48 h gently detached in the presence of 10 µM Y- 
27632, seeded at low density and further cultured in conditioned- 
medium. Single cell-derived colonies were picked, replated and 
Table 1 
Summary of lines.  
iPSC line Name Abbreviation in figure Gender Age Ethnicity Genotype of locus Disease 
UKEi070-A Het Female 53 Central America c.2308 G>A heterozygous HCM 
UKEi070-A1 Iso Co Female 53 Central America c.2308 G 
homozygous 
c.2308 G>T (silent) heterozygous  
UKEi070-A2 cpHet Female 53 Central America c.2308 G>A heterozygous c.2827C>T 
homozygous   
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eventually cryopreserved. For genotyping DNA was extracted using the 
QIAcube® HT workstation (Qiagen) and the QIAamp® 96 DNA QIA-
cube® HT Kit (Qiagen) according to the manufacturer‘s instruction. PCR 
amplification was performed with the DreamTaq DNA Polymerase 
(Thermo Fisher Scientific) and amplicons sequenced. 
3.3. Karyotyping 
Karyotype integrity of Het hiPSC was investigated at passage 6 by G- 
banding of 15 metaphases. Karyotypes of genetically modified hiPSC 
were verified with the NanoString nCounter® Human Karyotype Panel 
following the manufacturerś protocol (passage 31 Iso Co, passage 33 
cpHet). 
3.4. Flow cytometry 
For determination of pluripotency and cardiac differentiation by 
flow cytometry, we used anti-SSEA-3 and anti-cardiac troponin T (cTnT) 
antibodies, respectively, and compared to corresponding isotype con-
trols. Analysis was performed in the UKE FACS Core Facility using the 
Fig. 1. Characterization of hiPSC lines UKEi070-A (Het), UKEi070-A1 (Iso Co) and UKEi070-A2 (cpHet). A) Schematic depiction of MYBPC3 genetic status in the 
three lines. B) Normal morphology of the hiPSC colonies. C) G-Banding for the patient-specific cell line (Het) and NanoString nCounter human karyotype analysis 
after CRISPR/Cas9 genome editing revealed regular female karyotypes. D) Validation of the genetic status by Sanger sequencing of the three hiPSC lines. E) Flow 
cytometry analysis of the pluripotency marker SSEA-3 in several batches of hiPSC lines. F) RT-qPCR of the patient-specific cell line (Het) confirming specific gene 
expression on mRNA level. G) RT-PCR of pluripotency markers (NANOG and SOX2) in all three iPSC lines and markers of ectoderm (PAX6 and NCAM1) and 
endoderm (SOX17) after respective differentiation in vitro. H) Flow cytometry analysis of cardiac troponin T (cTnT)-positive cells after cardiac differentiation. I) 
Western blot of protein lysate from cardiomyocytes shows the absence of MYBPC3 in cpHet, confirming the bi-allelic truncating mutation. 
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FACSCanto II Flow Cytometer. 
3.5. Germ layer differentiation 
To verify the differentiation capacity of the hiPSC lines into all three 
germ layers, the STEMdiff Trilineage Differentiation Kit (StemCell 
Technologies, #05230) was used according to the manufacturerś in-
structions for endoderm and ectoderm. Mesodermal differentiation was 
shown by directed cardiac differentiation in a monolayer format. 
3.6. RNA isolation and RT-(q)PCR 
Total RNA was isolated from hiPSCs and differentiated cells with 
Trizol (Life Technologies), following the manufacturerś protocol. 
Reverse transcription of 200–500 ng of RNA was performed using Su-
perScript III First-Strand Synthesis System (Invitrogen) and oligd(T) as 
described in the datasheet. RT-(q)PCR was done for each gene of interest 
and beta-glucoronidase (GUSB) was used as housekeeping gene. 
3.7. Western blot 
For Western blot analysis protein lysates from hiPSC-CMs were 
separated on 10% SDS-polyacrylamide (29:1) mini-gels and transferred 
to nitrocellulose membrane. Used antibodies are listed in Table 3. 
Detection was performed with the Clarity Western ECL Substrate (Bio- 
Rad) and visualised with the ChemiDoc™ Touch Imaging System (Bio- 
Rad). 
3.8. Mycoplasma 
Absence of mycoplasma contamination was routinely assessed by 
PCR as previously described (Shibamiya et al., 2020). 
Table 2 
Characterization and validation.  
Classification Test Result Data 
Morphology Photography A visual record of the line’s cellular morphology: typical 
pluripotent human stem cell morphology 
Fig. 1 panel B  
Pluripotency status evidence for the described cell 
line 
Qualitative and quantitative 
Reverse Transcriptase - PCR 
Expression of pluripotent markers (NANOG and SOX2), 
ectoderm (NCAM1 and PAX6) and endoderm (SOX17) 
Fig. 1 panel G, Fig. 1 
panel F 
Quantitative analysis: Flow 
cytometry 
Assess % of positive cells for cell surface marker SSEA-3 Fig. 1 panel E  
Karyotype G-banding 
nCounter® Human Karyotype 
Panel 
Normal karyotype: 46, XX Fig. 1 panel C  
Genotyping for the desired genomic alteration/ 
allelic status of the gene of interest 
PCR across the edited site PCR + Sanger sequencing:  
- Isogenic control: correction of c.2308G>A and introduced 
silent mutation  
- Bi-allelic mutant: homozygous c.2827C>T 
Fig. 1 panel D 
Transgene-specific PCR N/A N/A  
Verification of the absence of random plasmid 
integration events 
PCR N/A N/A  
Parental and modified cell line genetic identity 
evidence 


















Provided, not shown   
Mutagenesis/genetic modification outcome 
analysis 
Sequencing (genomic DNA PCR) Sanger sequencing tracks Fig. 1 panel D 
PCR-based analyses Not performed Not performed 
Western Blot Absence of MYBPC3 in cpHet Fig. 1 panel D  
Off-target nuclease analysis PCR across the top ten predicted 
likely off-target sites 
Demonstration of the lack of NHEJ-caused mutagenesis in the 
top ten predicted off-target sites 
Supplemental Fig. 1  
Specific pathogen-free status Mycoplasma PCR Not shown  
Multilineage differentiation potential Directed differentiation Cardiac differentiation (mesoderm), Flow cytometry 
STEMdiff Trilineage Differentiation Kit 
Fig. 1 panel H 
Fig. 1 panel G  
Donor screening (OPTIONAL) HIV 1 + 2 Hepatitis B, Hepatitis C HIV 1 Taq-PCR QL, HBV-PCR HCV-PCR QL on primary 
fibroblasts under detection threshold 
Not shown  
Genotype – additional histocompatibility info 
(OPTIONAL) 
Blood group genotyping Not performed Not performed 
HLA tissue typing Not performed Not performed  





Reagents details.   
Antibody Dilution Company Cat # and RRID 
Pluripotency Marker Rat Anti-Human SSEA-3 Antibody, PE Conjugated 1:50 BD Biosciences Cat# 560237, RRID:AB_1645542 
Rat IgM, k antibody, BD Biosciences  BD Biosciences Cat# 553943, RRID:AB_10056839  
Cardiac differentiation marker Cardiac Troponin T Antibody, anti-human/mouse/rat, REAfinity™ 1:50 Miltenyi Biotec Cat# 130-119-674, RRID:AB_2751795 
REA Control Antibody (I), human IgG1, REAfinity™  Cat# 130-120-709, RRID:AB_2784399  
Western blot Anti-MYBPC3 1:2,000 Santa Cruz Biotechnology Cat# sc-137181, RRID:AB_2017318 
Anti-cTnT 1:3,000 Abcam Cat# ab8295, RRID:AB_306445 
Anti-mouse IgG HRP-conjugated 1:6,000 Sigma-Aldrich Cat# A9044, RRID:AB_258431  
Site-specific nuclease   
Nuclease information Alt-R® S.p. Cas9 Nuclease 3NLS, 2 nmol, Cat# 1081058  
Delivery method Nucleofection of the RNP complex (crRNA, tracrRNA) and Electroporation Enhancer Alt-R® CRISPR-Cas9 crRNA, 2 nmol (IDT®); 
Alt-R® CRISPR-Cas9 tracrRNA, ATTO™ 550, 5 nmol: Cat# 1075927 (IDT®); 
Alt-R® Cas9 Electroporation Enhancer, 10 nmol: Cat# 1075916 (IDT®)  
Selection/enrichment strategy N/A N/A  
Primers and Oligonucleotides used in this study Target Forward/Reverse primer (5′-3′) 
Reprogramming Vector (RT-qPCR) Sendai vector F: GGATCACTAGGTGATATCGAGC 
R: ACCAGACAAGAGTTTAAGAGATATGTATC  
Pluripotency Markers (RT-(q)PCR) NANOG (stem cell) F: GATTTGTGGGCCTGAAGAAA 
R: AAGTGGGTTGTTTGCCTTTG 
SOX2 (stem cell) F: AGTCTCCAAGCGACGAAAAA 
R: TTTCACGTTTGCAACTGTCC  
Differentiation markers (RT-(q)PCR) SOX17 (endodermal) F: CGCACGGAATTTGAACAGTA 
R: GGATCAGGGACCTGTCACAC 
PAX6 (ectodermal) F: TGGGCAGGTATTACGAGACTG 
R: ACTCCCGCTTATACTGGGCTA 




Housekeeping gene (RT-qPCR) GUSB F: AAACGATTGCAGGGTTTCAC 
R: CTCTCGTCGGTGACTGTTCA  
Mycoplasma detectione.g. Genotyping (desired allele/transgene 
presence detection) 
PCR specific for the targeted allele F: TGCACCATCTGTCACTCTGTTAACCTC 
R: ACTCCTACGGGAGGCAGCAGTA  
Targeted mutation analysis/sequencing Sequencing data from both alleles Isogenic control: exon 23 
F: GGCCTCTGGGGTCTGACT 
R: AGGCGGCTCCCACTGTACT 
Bi-allelic mutant: exon 27 
F: GCTGACAGAGCACACATCGA 
R: TTCTGGGCAGAGCATTCTGG  
crRNA sequence + PAM Isogenic crRNA + PAM: CACAGTCAAGGTCATCAGTG AGG  
Bi-allelic mutant crRNA + PAM: CCATATTGTGTGCCCGCACT CGG   
Genomic target sequence MYBPC3 NC_000011.10 (47331406..47352702, complement 
Isogenic crRNA + PAM: CACAGTCAAGGTCATCAGTG AGG 
Bi-allelic mutant crRNA + PAM: CCATATTGTGTGCCCGCACT CGG  
Top10 off-target (OT) mutagenesis predicted site sequencing 
primers 
Isogenic control + PAM: Isogenic control: 
OT1: CAGGCTCAAGGTCATCAGTG AGG OT1 F:CTGCCAAGAGGACCACAAGT 
(continued on next page) 
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Table 3 (continued ) 
OT2: CACAGTCAATGTCAACAGTG TGG R:AGTGGTTGTTGCTCTTCCCG 
OT3: TAAAGCCAAGGTCATCAGTG AAG OT2 F:GTCAGGGTGGAGGAGACAGA 
OT4: CATTGTCAAGGACATCAGTG GGG R: GCAACACCGGAAACTAGGAG 
OT5: GCCCTTCAAGGTCATCAGTG TGG OT3 F: TCATGATGGGTGGAGGTTGG 
OT6: CACAGTCAAGGACATCAGGG CAG R:TCTGGAAGTTCCTTGAAGGGG 
OT7: CAGAGTCAAAGTCATCAGGG TAG OT4 F: AGTTGGCCATGGCTGCTTAT 
OT8: CAGAATGCAGGTCATCAGTG CAG R: GGGGTGAACGAGTGCTTCTT 
OT9: CACTGTAAAGGCCATCAGTG TGG OT5 F: GCATTTTGGGGTGTTAAAAGTGC 
OT10: CTCTCTCATGGTCATCAGTG TAG R: TGAACTTGAGTGCAAGGCAGA  
OT6 F: TGGTTAGCTCATGTGCCACT  
R: TGTGTGGAACAGCTGAGCAT  
OT7 F: CCATCAGGACTGAGGGAAGC  
R: AAGGTGGGGTGGTCCTCTTA  
OT8 F: ACTGGAGGCCTTGGGAAAAA  
R: 5’-TCCGAGGGACCAGATCACTG  
OT9 F: GGGAGGATGGGGGAAAATAGC  
R: CAGCAGAAAGACTGCCTCGG  
OT10 F: CAGTGGCCTCTAAATCGGGG  
R: CTGAGAGGCGGATAGAAGCC 
Bi-allelic mutant: Bi-allelic mutant: 
OT1: CCAAGTTGTGTGCCTGCACT CAG OT1 F: TTACTTGGCCGTGTAGCCTG 
OT2: CAATATTGTATGCCTGCACT AAG R: CCATGGCTTCATGAGTAGGC 
OT3: GCTTATTTTGTGCCCGAACT TAG OT2 F: AGGGCTAAATCCATCAGCACC 
OT4: ACAAATTTTGTGCCCGCATT GAG R: TGGTGTATCCTGGACCATGC 
OT5: CCACAGTGTGTGCCTGCACT CGG OT3 F: CATTTACAGGCGTACTTCGCA 
OT6: CCTTATTGGCAGCCCGCACT CGG R: TCAGCATTTGTGAAAAGTGTCCC 
OT7: CTATATTTTCTGCCAGCACT GGG OT4 F: GCTTCAAAGGGTACAGAGCTA 
OT8: CCATTTTGTTCACCCGCACT TGG R: AGAAGGCAGGAAAAGATGAGTG 
OT9: CCTTAATGTCTGCCCGTACT TGG OT5 F: GCTAAGGAGCCTGTGTGGTT 
OT10: CCCTGGTGTGTGCCCGCAAT GGG R: TATCCCTACGGGAAGCCCAA  
OT6 F: GAGGAGGAGGATGGCTCTGA  
R: TCGGGGAAGTCGCCTACA  
OT7 F: TCCGAGTGAGCAAATCGCAT  
R: AGCAGGCCACTTTTCAGTGT  
OT8 F: TGGTAACTTCCACTCGCTGT  
R: GGCATCAGGTATCAGGTGTGT  
OT9 F: AAAGCAAAGCAGTGGGTCCT  
R: CCCCTCCCCTGCACATAGTA  
OT10 F: CTGCCTCCTTCCTGACTTGG  
R: AGACTCTACAGGGGCTGAGG  
120 mer ssODNs used as templates for HDR-mediated site- 
directed mutagenesis in antisense direction (5’ à 3’) 
Isogenic control template (+ silent mutation): CGGATGGGCCCTCCTTGGGGCTGC 
CCCTCTGTGTTCTCCAGCTTGGACCCCGGCCGGACTCACCGATGACCTTGACTGTGA 
GGTTTACCTGGTCCTCGCCCACAGGGTTCTTCACTGTGA  
Bi-allelic mutant template: 
ACTGTCACCGGCTCCGTGGTGGTAACCGGGGCTCCAGGCCCTGCCATATTGTGTGCC 
CGCACTCAGAAAAGCAGCCGGGCCCCCGTGGGCAGGTCCTTCACCAGTATTGATGTG 
TGCTCT   
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3.9. Short tandem repeat analysis 
STR analysis was performed with genomic DNA at the Center for 
Diagnostic, Institute of Legal Medicine UKE. 
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